Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis.
Rheumatology (Oxford)
; 60(12): 5527-5537, 2021 12 01.
Article
em En
| MEDLINE
| ID: mdl-33999135
ABSTRACT
OBJECTIVES:
Acute respiratory distress syndrome and cytokine release syndrome are the major complications of coronavirus disease 2019 (COVID-19) associated with increased mortality risk. We performed a meta-analysis to assess the efficacy and safety of anakinra in adult hospitalized non-intubated patients with COVID-19.METHODS:
Relevant trials were identified by searching literature until 24 April 2021 using the following terms anakinra, IL-1, coronavirus, COVID-19, SARS-CoV-2. Trials evaluating the effect of anakinra on the need for invasive mechanical ventilation and mortality in hospitalized non-intubated patients with COVID-19 were included.RESULTS:
Nine studies (n = 1119) were eligible for inclusion in the present meta-analysis. Their bias risk with reference to the assessed parameters was high. In pooled analyses, anakinra reduced the need for invasive mechanical ventilation (odds ratio (OR) 0.38, 95% CI 0.17-0.85, P = 0.02, I2 = 67%; six studies, n = 587) and mortality risk (OR 0.32, 95% CI 0.23-0.45, P < 0.00001, I2 = 0%; nine studies, n = 1119) compared with standard of care therapy. There were no differences regarding the risk of adverse events, including liver dysfunction (OR 0.75, 95% CI 0.48-1.16, P > 0.05, I2 = 28%; five studies, n = 591) and bacteraemia (OR 1.07, 95% CI 0.42-2.73, P > 0.05, I2 = 71%; six studies, n = 727).CONCLUSIONS:
Available evidence shows that treatment with anakinra reduces both the need for invasive mechanical ventilation and mortality risk of hospitalized non-intubated patients with COVID-19 without increasing the risk of adverse events. Confirmation of efficacy and safety requires randomized placebo-controlled trials.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Interleucina-1
/
Proteína Antagonista do Receptor de Interleucina 1
/
Tratamento Farmacológico da COVID-19
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article